A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension

Abstract

The pharmacokinetic (PK) parameters of lisinopril were obtained in 46 children aged 6 months to 15 years. A lisinopril suspension (0.15 mg/kg per day) was administered to patients n = 9), aged 6–23 months; Group II (n = 8), aged 2–5 years; Group III (n = 12), aged 6–11 years; Group IV (n = 17), aged 12–15 years. The dose of lisinopril ranged from 3.07 mg/m² per day in Group I to 4.78 mg/m² per day in Group IV. C_max of lisinopril, which occurred 5–6 h postdose, varied from 22 ng/ml in Groups I and II to 44 ng/ml in Groups III and IV; AUC_0–24 h ranged from 301–311 ng·h/ml in Groups I and II to 550–570 ng·h/ml in Groups III and IV. No serious adverse events related to lisinopril were reported.